Cytomegalovirus (CMV) retinitis is a sight-threatening opportunistic infection of the retina caused by reactivation of latent cytomegalovirus in immunocompromised hosts, most classically people with advanced HIV/AIDS and low CD4 counts, as well as transplant and immunosuppressed patients. Productive CMV infection produces a progressive, full-thickness necrotizing retinitis that can rapidly lead to retinal detachment and irreversible blindness if untreated. It is historically notable as the indication for fomivirsen, the first antisense oligonucleotide drug ever approved by the FDA (1998).
Ask a research question about Cytomegalovirus Retinitis. OpenScientist will conduct autonomous deep research using the Disorder Mechanisms Knowledge Base and PubMed literature (typically 10-30 minutes).
Do not include personal health information in your question. Questions and results are cached in your browser's local storage.
name: Cytomegalovirus Retinitis
creation_date: '2026-05-30T12:00:00Z'
description: >-
Cytomegalovirus (CMV) retinitis is a sight-threatening opportunistic infection
of the retina caused by reactivation of latent cytomegalovirus in
immunocompromised hosts, most classically people with advanced HIV/AIDS and
low CD4 counts, as well as transplant and immunosuppressed patients. Productive
CMV infection produces a progressive, full-thickness necrotizing retinitis that
can rapidly lead to retinal detachment and irreversible blindness if untreated.
It is historically notable as the indication for fomivirsen, the first antisense
oligonucleotide drug ever approved by the FDA (1998).
category: Infectious Disease
disease_term:
preferred_term: cytomegalovirus retinitis
term:
id: MONDO:0000878
label: cytomegalovirus retinitis
parents:
- Cytomegalovirus infection
- Viral eye infection
- Opportunistic infection
infectious_agent:
- name: Human cytomegalovirus
infectious_agent_term:
preferred_term: Human cytomegalovirus
term:
id: NCBITaxon:10359
label: Human betaherpesvirus 5
description: >-
Human cytomegalovirus (HCMV, human betaherpesvirus 5) is a ubiquitous
betaherpesvirus that establishes lifelong latency after primary infection and
reactivates to cause end-organ disease, including retinitis, when host cellular
immunity is impaired.
evidence:
- reference: PMID:11294581
reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An important proportion of immunodepressed patients are latent carriers of
the virus, and under these conditions, the lack of cellular immunity
predisposes the patient to an active infection in which the virus is
replicating.
explanation: Establishes that CMV persists latently and reactivates to active replication when cellular immunity is lost.
- reference: PMID:21168815
reference_title: "Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "With immune deficiency, such as late-stage AIDS, CMV reactivates, is disseminated to the eye, and establishes a productive infection, resulting in retinal necrosis."
explanation: >-
Names cytomegalovirus as the organism whose productive ocular infection
produces the retinal necrosis this entry curates.
transmission:
- name: Acquisition by blood, body fluids, transplantation, and vertical transmission
description: >-
Cytomegalovirus is acquired from an infected person by contact with blood or
body fluids, through transplanted organs, or from mother to child. Primary
infection is usually unremarkable in an immunocompetent host, and the
retinitis this entry describes is never the presentation of that first
encounter.
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "Cytomegalovirus (CMV) is a ubiquitous herpesvirus transmitted via blood, body fluids, organ transplants, and vertical transmission."
explanation: >-
Enumerates the routes by which the virus is acquired. Evidence source is
OTHER because this is a review.
- name: Reactivation of latent virus and haematogenous spread to the retina
description: >-
The route that matters clinically is not acquisition but delivery to the
eye. After primary infection the virus persists latently for life; when
cellular immunity fails, it reactivates and disseminates through the blood
to the retina. Retinitis is therefore an endogenous, bloodborne event in a
host infected long beforehand, which is why it tracks CD4 count and
immunosuppression rather than any recent exposure.
evidence:
- reference: PMID:21168815
reference_title: "Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "With immune deficiency, such as late-stage AIDS, CMV reactivates, is disseminated to the eye, and establishes a productive infection, resulting in retinal necrosis."
explanation: >-
States the reactivation-then-dissemination sequence by which the virus
reaches the retina in an immunodeficient host.
- reference: PMID:11294581
reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An important proportion of immunodepressed patients are latent carriers of
the virus, and under these conditions, the lack of cellular immunity
predisposes the patient to an active infection in which the virus is
replicating.
explanation: >-
Establishes the latent-carrier reservoir and the loss of cellular immunity
that permits the reactivation this route depends on.
pathophysiology:
- name: CMV reactivation under impaired cellular immunity
description: >-
In hosts with deficient CD4+ T-cell-mediated immunity (advanced HIV/AIDS,
transplant recipients, or other iatrogenic immunosuppression), latent
cytomegalovirus escapes immune control and resumes active replication. Loss of
protective cellular immunity is the proximal permissive event for end-organ CMV
disease.
downstream:
- target: Productive CMV infection of the retina
description: Reactivated, replicating virus disseminates and seeds the retina.
cell_types:
- preferred_term: CD4-positive T cell
term:
id: CL:0000624
label: CD4-positive, alpha-beta T cell
modifier: DECREASED
biological_processes:
- preferred_term: adaptive immune response
modifier: DECREASED
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: viral genome replication
modifier: INCREASED
term:
id: GO:0019079
label: viral genome replication
evidence:
- reference: PMID:11294581
reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
An important proportion of immunodepressed patients are latent carriers of
the virus, and under these conditions, the lack of cellular immunity
predisposes the patient to an active infection in which the virus is
replicating.
explanation: Directly links loss of cellular immunity to reactivation and active CMV replication.
- name: Productive CMV infection of the retina
description: >-
Replicating cytomegalovirus reaches the eye and productively infects retinal
cells. In profoundly immunosuppressed HIV-positive patients, the retina is one
of the most characteristic sites of CMV end-organ disease.
downstream:
- target: Full-thickness necrotizing retinitis
description: Cytopathic viral infection drives inflammation and retinal cell destruction.
cell_types:
- preferred_term: retinal pigment epithelial cell
term:
id: CL:0002586
label: retinal pigment epithelial cell
- preferred_term: photoreceptor cell
term:
id: CL:0000210
label: photoreceptor cell
biological_processes:
- preferred_term: viral process
modifier: INCREASED
term:
id: GO:0016032
label: viral process
evidence:
- reference: PMID:11294581
reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In HIV-positive patients, CMVD tends to manifest itself as retinitis and
involvement of the gastrointestinal tract.
explanation: Supports the retina as a principal site of CMV end-organ disease in HIV-positive patients.
- name: Full-thickness necrotizing retinitis
description: >-
Productive retinal CMV infection produces a progressive, full-thickness
necrotizing retinitis with retinal opacification from necrosis and associated
intraretinal hemorrhage. It typically begins in the peripheral retina and
advances toward the posterior pole, and untreated it can rapidly destroy the
retina, leading to blindness.
downstream:
- target: Immune recovery uveitis
description: Restoration of immunity in a retina bearing prior CMV antigen can trigger paradoxical intraocular inflammation.
biological_processes:
- preferred_term: cell death
modifier: INCREASED
term:
id: GO:0008219
label: cell death
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:12768225
reference_title: Fomivirsen.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients
with acquired immune deficiency syndrome (AIDS).
explanation: Supports rapid progression of CMV retinitis to blindness in AIDS.
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "which could develop to the characteristic “pizza pie” appearance marked by central retinal necrosis and intraretinal hemorrhage"
explanation: >-
Supports the necrosis-plus-hemorrhage morphology recorded on this node.
Evidence source is OTHER because this is a narrative clinical review.
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "Retinopathy typically begins in the peripheral retina and gradually advances toward the posterior pole"
explanation: >-
Supports the direction of spread recorded in this node's description,
which previously described it as centrifugal. Evidence source is OTHER
because this is a narrative clinical review.
- name: Immune recovery uveitis
description: >-
When cellular immunity is restored, most often after initiation of
antiretroviral therapy in HIV/AIDS, a paradoxical intraocular inflammatory
reaction can develop in eyes with prior CMV retinitis. This immune recovery
uveitis is an important cause of visual morbidity despite control of the
underlying viral infection.
biological_processes:
- preferred_term: adaptive immune response
modifier: INCREASED
term:
id: GO:0002250
label: adaptive immune response
- preferred_term: inflammatory response
modifier: INCREASED
term:
id: GO:0006954
label: inflammatory response
evidence:
- reference: PMID:39046420
reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
It is a paradoxical reaction that is frequently associated with a prior
cytomegalovirus retinitis infection.
explanation: Supports immune recovery uveitis as a paradoxical inflammatory sequela of prior CMV retinitis.
phenotypes:
- category: Ophthalmological
name: Retinitis
description: Necrotizing inflammation of the retina is the defining feature of the disease.
phenotype_term:
preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: PMID:11294581
reference_title: Laboratory diagnosis of cytomegalovirus (CMV) infections in immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In HIV-positive patients, CMVD tends to manifest itself as retinitis and
involvement of the gastrointestinal tract.
explanation: Supports retinitis as the characteristic ocular manifestation of CMV in HIV-positive patients.
- category: Ophthalmological
name: Yellow-white retinal lesions
description: >-
Retinal opacification from necrosis, accompanied by intraretinal hemorrhage,
gives the characteristic "pizza pie" fundus appearance. Lesions typically
begin in the peripheral retina and progress toward the posterior pole.
phenotype_term:
preferred_term: Yellow-white retinal lesions
term:
id: HP:0030506
label: Yellow/white retinal lesion
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "which could develop to the characteristic “pizza pie” appearance marked by central retinal necrosis and intraretinal hemorrhage"
explanation: >-
Gives the lesion morphology recorded here -- retinal necrosis with
intraretinal hemorrhage. Evidence source is OTHER because this is a
narrative clinical review.
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "Lesions typically begin peripherally and progress toward the posterior pole"
explanation: >-
Supports the distribution and direction of spread stated in the
description. Evidence source is OTHER because this is a narrative clinical
review.
- reference: PMID:32318357
reference_title: "Clinical Features of Cytomegalovirus Retinitis in HIV Infected Patients."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the yellow-white retinal lesions gradually disappeared"
explanation: >-
Confirms yellow-white retinal lesions as the characteristic fundus
finding of active CMV retinitis, documented as resolving after
antiretroviral-driven immune recovery.
- category: Ophthalmological
name: Visual impairment
description: >-
Retinal destruction reduces visual acuity. Untreated disease causes vision
loss, and loss can continue to accrue even where antiviral treatment improves
acuity in the short term.
phenotype_term:
preferred_term: Visual impairment
term:
id: HP:0000505
label: Visual impairment
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "CMVR causes vision loss if left untreated, and early antiviral therapy significantly reduces the risk of vision loss."
explanation: >-
States the untreated outcome and the effect of early treatment. Evidence
source is OTHER because this is a narrative clinical review.
- reference: PMID:37452370
reference_title: Comparison of two different intravitreal treatment regimens combined with systemic antiviral therapy for cytomegalovirus retinitis in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "while vision loss from CMVR continued to occur at the 12-month visit"
explanation: >-
Supports the residual, treatment-refractory component of visual loss
recorded in the description, in a randomized intravitreal-ganciclovir
trial.
- reference: PMID:21168815
reference_title: "Cytomegalovirus retinitis and the acquired immunodeficiency syndrome--bench to bedside: LXVII Edward Jackson Memorial Lecture."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "rates of visual loss to 20/50 or worse (visual impairment) were 0.94-0.98/EY and to 20/200 or worse (blindness) 0.47-0.49/EY"
explanation: >-
Quantifies the rate of visual impairment (visual acuity 20/50 or worse)
in treated CMV retinitis patients in the pre-HAART era.
- category: Ophthalmological
name: Vitreous floaters
description: >-
Floaters are among the nonspecific initial symptoms of CMV retinitis, along
with blurred vision and flashing lights.
phenotype_term:
preferred_term: Vitreous floaters
term:
id: HP:0100832
label: Vitreous floaters
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "The initial CMVR symptoms are nonspecific, often including blurred vision, floaters, and flashing lights"
explanation: >-
Names floaters among the presenting symptoms and records their
nonspecificity. Evidence source is OTHER because this is a narrative
clinical review.
- reference: DOI:10.3389/fcimb.2023.1107237
reference_title: "Clinical features of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome and efficacy of the current therapy"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common symptoms were blurred vision (55%, 95%CI 46%-65%), followed by asymptomatic, visual field defect, and floaters."
explanation: >-
Meta-analysis of 20,214 CMVR patients lists floaters among the most
common presenting symptoms.
- category: Ophthalmological
name: Scotoma
description: >-
Blind spots appear as the retinitis progresses, corresponding to areas of
retinal necrosis.
phenotype_term:
preferred_term: Scotoma
term:
id: HP:0000575
label: Scotoma
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "As the disease progresses, patients may experience floaters, flashes of light, and blind spots"
explanation: >-
Names blind spots (scotomata) among the symptoms that appear as the
disease progresses. Evidence source is OTHER because this is a narrative
clinical review.
- reference: DOI:10.3389/fcimb.2023.1107237
reference_title: "Clinical features of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome and efficacy of the current therapy"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The most common symptoms were blurred vision (55%, 95%CI 46%-65%), followed by asymptomatic, visual field defect, and floaters."
explanation: >-
Meta-analysis of 20,214 CMVR patients lists visual field defect
(the presenting-symptom category a localized scotoma falls under) among
the most common presenting symptoms.
- category: Ophthalmological
name: Retinal detachment
description: >-
Holes in areas of retinal necrosis lead to rhegmatogenous retinal detachment,
a frequent complication of CMV retinitis and a major cause of vision loss.
phenotype_term:
preferred_term: Retinal detachment
term:
id: HP:0000541
label: Retinal detachment
evidence:
- reference: PMID:11139700
reference_title: "[Current status of retinal detachment in AIDS patients]."
supports: SUPPORT
evidence_source: OTHER
snippet: "Multiple or single holes, as well as micro holes, were observed in areas of retinal necrosis leading to complex retinal detachments."
explanation: >-
Gives the mechanism recorded here -- breaks forming within necrotic retina
and producing detachment. Evidence source is OTHER because this is a
narrative review of clinical experience.
- reference: PMID:11139700
reference_title: "[Current status of retinal detachment in AIDS patients]."
supports: SUPPORT
evidence_source: OTHER
snippet: "Retinal detachment (RD) is a frequent complication of this disease, with an incidence varying from 18% to 29%."
explanation: >-
Quantifies how frequent the complication is, supporting its description as
a major complication rather than a rarity. Evidence source is OTHER because
this is a narrative review of clinical experience.
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "When untreated, the disease can lead to retinal detachment, a major cause of vision loss"
explanation: >-
Independent statement that detachment is a major route to vision loss in
untreated disease. Evidence source is OTHER because this is a narrative
clinical review.
- reference: DOI:10.3389/fcimb.2023.1107237
reference_title: "Clinical features of Cytomegalovirus retinitis in patients with acquired immunodeficiency syndrome and efficacy of the current therapy"
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "The general incidence of CMVR-related RD in the entire course was 24% (95%CI 18%-29%)"
explanation: >-
Quantifies retinal detachment as a common complication across the
course of CMV retinitis in a meta-analysis of 20,214 patients.
- category: Ophthalmological
name: Blindness
description: Untreated or progressive disease can rapidly lead to irreversible blindness.
phenotype_term:
preferred_term: Blindness
term:
id: HP:0000618
label: Blindness
evidence:
- reference: PMID:12768225
reference_title: Fomivirsen.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Cytomegalovirus (CMV) retinitis can rapidly lead to blindness in patients
with acquired immune deficiency syndrome (AIDS).
explanation: Supports blindness as the major outcome of untreated CMV retinitis.
- category: Ophthalmological
name: Immune recovery uveitis
description: >-
Intraocular inflammation arising after immune reconstitution in eyes with
prior CMV retinitis.
phenotype_term:
preferred_term: Uveitis
term:
id: HP:0000554
label: Uveitis
evidence:
- reference: PMID:39046420
reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Immune recovery uveitis is an important cause of visual morbidity
particularly in HIV/AIDS patients receiving highly active antiretroviral.
explanation: Supports uveitis (immune recovery uveitis) as a cause of visual morbidity after antiretroviral therapy.
treatments:
- name: Fomivirsen
description: >-
Fomivirsen (Vitravene) is an intravitreally administered antisense
oligonucleotide complementary to cytomegalovirus immediate-early region 2 (IE2)
mRNA. Approved by the FDA in 1998, it was the first antisense oligonucleotide
drug ever approved and was used for CMV retinitis in AIDS patients, including
relapsed disease unresponsive to conventional antivirals.
therapeutic_modality: ANTISENSE_OLIGONUCLEOTIDE
oligonucleotide_details:
oligonucleotide_mechanism: RNASE_H_KNOCKDOWN
target_transcript: CMV IE2 mRNA
oligonucleotide_chemistry: PHOSPHOROTHIOATE
conjugation: UNCONJUGATED
delivery_platform: UNFORMULATED
treatment_term:
preferred_term: Pharmacotherapy
term:
id: NCIT:C15986
label: Pharmacotherapy
therapeutic_agent:
- preferred_term: fomivirsen
term:
id: NCIT:C174902
label: Fomivirsen
target_mechanisms:
- target: Productive CMV infection of the retina
treatment_effect: INHIBITS
description: >-
Antisense knockdown of CMV immediate-early region 2 (IE2) mRNA suppresses
viral immediate-early gene expression, blocking productive replication of
cytomegalovirus in the retina.
target_phenotypes:
- preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: PMID:12768225
reference_title: Fomivirsen.
supports: SUPPORT
evidence_source: OTHER
snippet: >-
Fomivirsen is a novel antisense drug with a 21-nucleotide sequence
complementary to the immediate early region 2 of CMV messenger ribonucleic
acid.
explanation: >-
Establishes fomivirsen's antisense mechanism targeting CMV IE2 mRNA.
Evidence source is OTHER because this sentence is a molecular
characterization of the drug, not a human clinical observation.
- reference: PMID:11497353
reference_title: "Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision."
supports: SUPPORT
evidence_source: OTHER
snippet: "fomivirsen is the first antisense oligonucleotide to receive approval for licensing"
explanation: >-
Source for the historical priority claim made in this entry's description
and in this treatment. Evidence source is OTHER because this is a drug
technology evaluation rather than a primary study.
- reference: PMID:11497353
reference_title: "Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision."
supports: SUPPORT
evidence_source: OTHER
snippet: "In August 1998, the FDA approved the marketing of Vitravene for the local treatment of CMV retinitis"
explanation: >-
Gives the 1998 FDA approval date and the CMV retinitis indication recorded
in the description. Evidence source is OTHER because this is a drug
technology evaluation rather than a primary study.
- reference: PMID:11497353
reference_title: "Technology evaluation: fomivirsen, Isis Pharmaceuticals Inc/CIBA vision."
supports: SUPPORT
evidence_source: OTHER
snippet: "Fomivirsen (ISIS-2922, Vitravene) is an antisense 21 mer phosphorothioate oligonucleotide"
explanation: >-
Source for the PHOSPHOROTHIOATE backbone chemistry recorded in
oligonucleotide_details. Evidence source is OTHER because this is a drug
technology evaluation rather than a primary study.
- reference: PMID:12768225
reference_title: Fomivirsen.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
In clinical trials, fomivirsen was shown to provide effective treatment for
newly diagnosed, peripheral CMV retinitis in patients with AIDS and in those
with relapsed CMV retinitis that is unresponsive to conventional therapy.
explanation: Supports clinical efficacy of fomivirsen for newly diagnosed and relapsed CMV retinitis.
- reference: PMID:38914784
reference_title: Mechanisms of Action of the US Food and Drug Administration-Approved Antisense Oligonucleotide Drugs.
supports: SUPPORT
evidence_source: OTHER
snippet: "fomiversen (for opportunistic cytomegalovirus infection)"
explanation: Lists fomivirsen among FDA-approved antisense oligonucleotide drugs, for opportunistic CMV infection.
- name: Intravitreal ganciclovir
description: >-
Intravitreal ganciclovir delivers high local antiviral drug concentrations to
control CMV retinitis, used alone or combined with systemic antiviral therapy.
treatment_term:
preferred_term: antiviral agent therapy
term:
id: NCIT:C16119
label: Antiviral Therapy
therapeutic_agent:
- preferred_term: ganciclovir
term:
id: CHEBI:465284
label: ganciclovir
target_mechanisms:
- target: Productive CMV infection of the retina
treatment_effect: INHIBITS
description: >-
Ganciclovir inhibits CMV DNA polymerase, suppressing productive viral
replication in the retina; intravitreal delivery achieves high local
antiviral concentrations.
target_phenotypes:
- preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: PMID:37452370
reference_title: Comparison of two different intravitreal treatment regimens combined with systemic antiviral therapy for cytomegalovirus retinitis in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "the median BCVA, expressed as the logarithm of the minimum angle of resolution (logMAR), improved significantly from baseline to the end of treatment"
explanation: >-
The trial's result: visual acuity improved significantly on intravitreal
ganciclovir. Note this was a low- versus intermediate-dose comparison, so
it establishes benefit within the treated arms rather than against no
treatment.
- name: Oral valganciclovir
description: >-
Oral valganciclovir is a prodrug of ganciclovir providing systemic anti-CMV
therapy for induction and maintenance treatment of CMV retinitis.
treatment_term:
preferred_term: antiviral agent therapy
term:
id: NCIT:C16119
label: Antiviral Therapy
therapeutic_agent:
- preferred_term: valganciclovir
term:
id: CHEBI:63635
label: valganciclovir
target_mechanisms:
- target: Productive CMV infection of the retina
treatment_effect: INHIBITS
description: >-
Valganciclovir is an oral prodrug of ganciclovir that provides systemic
inhibition of CMV DNA polymerase, suppressing productive viral replication
for induction and maintenance therapy.
target_phenotypes:
- preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: NCIT:C2629
reference_title: "Valganciclovir (NCIT)"
supports: SUPPORT
evidence_source: OTHER
snippet: "Valganciclovir | Accepted_Therapeutic_Use_For | - | - | Cytomegalovirus retinitis"
explanation: >-
NCI Thesaurus asserts accepted therapeutic use of valganciclovir for
cytomegalovirus retinitis.
- name: Foscarnet
description: >-
Foscarnet is a pyrophosphate analogue antiviral used for CMV retinitis as an
alternative to ganciclovir, given intravenously or intravitreally,
particularly in drug-resistant disease or when ganciclovir is not tolerated.
treatment_term:
preferred_term: antiviral agent therapy
term:
id: NCIT:C16119
label: Antiviral Therapy
therapeutic_agent:
- preferred_term: foscarnet
term:
id: NCIT:C71630
label: Foscarnet
target_mechanisms:
- target: Productive CMV infection of the retina
treatment_effect: INHIBITS
description: >-
Foscarnet inhibits the viral DNA polymerase by binding its
pyrophosphate-binding site -- a mechanism distinct from the nucleoside and
nucleotide analogues -- suppressing productive viral replication.
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "FOS uniquely inhibits viral DNA polymerase by binding to its pyrophosphate binding site"
explanation: >-
States the pyrophosphate-binding-site mechanism this link asserts.
Evidence source is OTHER because this is a narrative clinical review.
target_phenotypes:
- preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "FOS, with a different mechanism of action than GCV, serves as an alternative treatment option for intravenous and intravitreal administration"
explanation: >-
Places foscarnet as a mechanistically distinct alternative to ganciclovir,
given intravenously or intravitreally -- the role recorded in this
treatment's description. The same review sentence continues by naming
drug-resistant patients as the particular indication; that clause sits
after a bracketed citation marker and so could not be quoted contiguously.
Note the review says drug-resistant rather than specifically
ganciclovir-resistant, which is why the description is worded that way.
Evidence source is OTHER because this is a narrative clinical review.
- reference: PMID:8011248
reference_title: "Phase II dose-ranging trial of foscarnet salvage therapy for cytomegalovirus retinitis in AIDS patients intolerant of or resistant to ganciclovir (ACTG protocol 093). AIDS Clinical Trials Group of the National Institute of Allergy and Infectious Diseases."
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "In patients who exhibited clinical resistance to ganciclovir, foscarnet appeared to have efficacy in controlling retinitis."
explanation: >-
Randomized phase II trial supporting foscarnet efficacy in
ganciclovir-resistant CMV retinitis.
- name: Antiretroviral therapy for immune reconstitution
description: >-
In HIV/AIDS-associated CMV retinitis, antiretroviral therapy raises the CD4+
T-cell count, and that immune recovery has been effective in controlling
opportunistic infections: in some patients retinitis has not progressed even
after specific anti-CMV therapy was stopped, and anti-CMV maintenance therapy
can likely be discontinued safely in selected patients with a sustained CD4+
response. The same immune recovery can precipitate immune recovery uveitis.
treatment_term:
preferred_term: antiretroviral therapy
term:
id: NCIT:C94631
label: Antiretroviral Therapy
target_mechanisms:
- target: CMV reactivation under impaired cellular immunity
treatment_effect: RESTORES
description: >-
Antiretroviral therapy raises CD4+ T-cell counts, and the resulting immune
recovery controls the opportunistic infection that the immunodeficiency
permitted -- to the point that specific anti-CMV therapy can be withdrawn
without retinitis progression in some patients.
evidence:
- reference: PMID:10665706
reference_title: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
supports: SUPPORT
evidence_source: OTHER
snippet: "Immune recovery in patients receiving HAART has been effective in controlling opportunistic infections, but it may also result in intraocular inflammation, which can have adverse effects on the eye."
explanation: >-
States that HAART-driven immune recovery controls opportunistic
infection, which is the claim this RESTORES link makes, together with
the intraocular-inflammation trade-off. Evidence source is OTHER because
this is a narrative clinical review rather than a primary study.
- reference: PMID:10665706
reference_title: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
supports: SUPPORT
evidence_source: OTHER
snippet: "In some patients, retinitis has not progressed when specific anti-CMV therapy was discontinued"
explanation: >-
Carries the withdrawal clause of this link's description, which the
immune-recovery quote above does not reach: retinitis stayed quiescent
after specific anti-CMV therapy was stopped. Evidence source is OTHER
because this is a narrative clinical review rather than a primary study.
evidence:
- reference: PMID:10665706
reference_title: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
supports: SUPPORT
evidence_source: OTHER
snippet: "In some patients, retinitis has not progressed when specific anti-CMV therapy was discontinued"
explanation: >-
The clinical observation behind the durable-control claim: with immune
recovery on HAART, retinitis can remain quiescent after anti-CMV drugs are
stopped. Evidence source is OTHER because this is a narrative clinical
review rather than a primary study.
- reference: PMID:10665706
reference_title: Cytomegalovirus retinitis in the era of highly active antiretroviral therapy.
supports: SUPPORT
evidence_source: OTHER
snippet: "Anti-CMV maintenance therapy likely can be safely discontinued in some patients with CMV retinitis if CD4+ cell counts are stable or increasing"
explanation: >-
Ties the ability to withdraw maintenance antiviral therapy to a sustained
CD4+ recovery, which is the immune-reconstitution mechanism this treatment
targets. Evidence source is OTHER because this is a narrative clinical
review rather than a primary study.
- reference: PMID:39046420
reference_title: "Immune recovery uveitis: an ocular manifestation in HIV/AIDS receiving treatment."
supports: SUPPORT
directness: DIRECT
evidence_source: HUMAN_CLINICAL
snippet: >-
Immune recovery uveitis is an important cause of visual morbidity
particularly in HIV/AIDS patients receiving highly active antiretroviral.
explanation: >-
Directly asserts the adverse half of this treatment's description -- the
immune recovery uveitis that antiretroviral-driven immune recovery can
precipitate. It says nothing about the antiviral-control benefit, which is
carried by the separate mechanism-link evidence above.
- name: Cidofovir
description: >-
Cidofovir (Vistide) is an intravenous nucleotide analogue antiviral approved
by the FDA for CMV retinitis in AIDS patients, particularly for relapsing or
ganciclovir-resistant disease. Its prolonged intracellular half-life allows
biweekly maintenance dosing. Must be co-administered with oral probenecid and
intravenous saline hydration to minimize nephrotoxicity.
treatment_term:
preferred_term: antiviral agent therapy
term:
id: NCIT:C16119
label: Antiviral Therapy
therapeutic_agent:
- preferred_term: cidofovir
term:
id: NCIT:C1600
label: Cidofovir
target_mechanisms:
- target: Productive CMV infection of the retina
treatment_effect: INHIBITS
description: >-
Cidofovir, a nucleotide analogue, inhibits CMV DNA polymerase and
suppresses productive viral replication; its prolonged intracellular
half-life supports biweekly maintenance dosing.
target_phenotypes:
- preferred_term: Retinitis
term:
id: HP:0032118
label: Retinitis
evidence:
- reference: PMID:9036797
reference_title: >-
Intravenous cidofovir for peripheral cytomegalovirus retinitis in patients
with AIDS. A randomized, controlled trial.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Cidofovir was efficacious in delaying progression of previously untreated CMV retinitis."
explanation: >-
Randomized controlled trial demonstrating cidofovir efficacy for
previously untreated peripheral CMV retinitis in AIDS patients.
diagnosis:
- name: CD4+ lymphocyte count and CMV risk stratification
description: >-
CMV retinitis occurs almost exclusively in patients with severely impaired
cellular immunity. CD4+ lymphocyte count below 50 cells/mm³ is the principal
immunological threshold identifying patients at highest risk for CMV end-organ
disease; other concurrent opportunistic infections are also a risk marker.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: NCIT:C18020
label: Diagnostic Procedure
evidence:
- reference: PMID:11294581
reference_title: >-
Laboratory diagnosis of cytomegalovirus (CMV) infections in
immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
appears almost exclusively in patients with a CD4+ lymphocyte count lower
than 50/mm3 and when other opportunistic infections have occurred.
explanation: >-
Establishes CD4+ count below 50/mm³ as the key risk threshold identifying
HIV-positive patients at highest risk for CMV end-organ disease.
- name: CMV viral load quantification (pp65 antigenemia and quantitative PCR)
description: >-
Active CMV infection is confirmed and monitored by quantitative viral load
methods, primarily pp65 antigenemia and quantitative PCR. These assays
identify patients with high viral burden at risk of progressing to CMV
disease and guide pre-emptive antiviral treatment. Shell-vial rapid culture
is an alternative for rapid diagnosis of active infection.
diagnosis_term:
preferred_term: diagnostic procedure
term:
id: NCIT:C18020
label: Diagnostic Procedure
evidence:
- reference: PMID:11294581
reference_title: >-
Laboratory diagnosis of cytomegalovirus (CMV) infections in
immunodepressed patients, mainly in patients with AIDS.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Techniques allowing the quantification of CMV viremia, namely pp65
antigenemia and quantitative PCR, have been most useful to this end.
explanation: >-
Supports pp65 antigenemia and quantitative PCR as primary methods for
quantifying CMV viremia and identifying high-risk patients for
pre-emptive antiviral therapy.
prevalence:
- population: HIV-positive patients (worldwide)
measure_type: LIFETIME_PREVALENCE
prevalence_class: ABOVE_1_IN_1000
rate_per_100000: 30000.0
rate_low: 20000.0
rate_high: 40000.0
notes: >-
Cumulative proportion of HIV-positive patients who develop CMV retinitis
over the course of their HIV disease. The figure derives from the
pre-HAART literature, where 25-42% of AIDS patients developed CMVR; it is
not a current-era point prevalence, and it is not comparable with the
post-HAART annual incidence recorded below, which is roughly 400-fold
lower.
evidence:
- reference: PMID:39339903
reference_title: "Cytomegalovirus Retinitis: Clinical Manifestations, Diagnosis and Treatment."
supports: SUPPORT
evidence_source: OTHER
snippet: "affecting approximately 20–40% of human immunodeficiency virus (HIV)-positive patients"
explanation: >-
Review giving the proportion of HIV-positive patients affected by CMV
retinitis over the course of disease. The cited sentence carries no
temporal qualifier, and the same statistic is phrased in the pre-HAART
literature as the proportion of AIDS patients who develop CMVR, so it is
recorded as a lifetime rather than a point prevalence. Evidence source
is OTHER because this is a narrative clinical review, consistent with
every other citation of this reference in this file.
- population: >-
HIV-positive patients, single US institution cohort, 1992-1993
(pre-HAART)
measure_type: ANNUAL_INCIDENCE
rate_per_100000: 2600.0
rate_denominator: POPULATION_PER_YEAR
notes: >-
Pre-HAART-era new-CMVR-diagnosis rate at one US practice, before the
advent of protease inhibitors. The source reviews a 1992-1993 window,
roughly two years, against the one-year October 1997 - October 1998 window
of the post-HAART record below, so the two rates are not annualized on an
identical basis and the pre/post contrast is the reliable reading rather
than either absolute figure.
evidence:
- reference: PMID:10935050
reference_title: >-
Effect of highly active antiretroviral therapy on the incidence of
HIV-related cytomegalovirus retinitis and retinal detachment.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: "Twenty five (2.6%) of 974 HIV+ patients in group 1 developed CMVR."
explanation: >-
Reports the pre-HAART annual incidence of new CMV retinitis diagnoses
at a single institution.
- population: >-
HIV-positive patients, same US institution cohort, 1997-1998
(after widespread HAART use)
measure_type: ANNUAL_INCIDENCE
rate_per_100000: 70.0
rate_denominator: POPULATION_PER_YEAR
notes: >-
Same institution's cohort after widespread HAART adoption, a 99%
reduction from the pre-HAART rate reported in the same study. Window is
October 1997 to October 1998.
evidence:
- reference: PMID:10935050
reference_title: >-
Effect of highly active antiretroviral therapy on the incidence of
HIV-related cytomegalovirus retinitis and retinal detachment.
supports: SUPPORT
evidence_source: HUMAN_CLINICAL
snippet: >-
Only 1 patient (0.07%) of 1274 patients in group 3 developed CMVR,
which represents a 99% reduction since 1993
explanation: >-
Reports the post-HAART annual incidence of new CMV retinitis
diagnoses at the same institution, quantifying the HAART-era decline.
mappings:
mondo_mappings:
- term:
id: MONDO:0000878
label: cytomegalovirus retinitis
mapping_predicate: skos:exactMatch
mapping_source: MONDO
mapping_justification: MONDO provides an exact disease term for cytomegalovirus retinitis.
ncit_mappings:
- term:
id: NCIT:C50521
label: Cytomegaloviral Retinitis
mapping_predicate: skos:exactMatch
mapping_source: NCIT
mapping_justification: NCIT provides an exact term for cytomegalovirus retinitis; cross-referenced from MONDO:0000878.